Please assess the completion status of the following clinical trial:

Trial Title: NUDGE-EHR Replication Trial at Mass General Brigham

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary care provider at Mass General Brigham~Providers will receive these EHR tools for their patients who meet the following criteria:~1. older adults (aged 65 years or more)~2. who have been prescribed at least 90 pills of benzodiazepine or sedative hypnotic in the last 180 days.~Outcomes will be measured on the patient level.~Exclusion Criteria:~* N/A

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Alert (Usual Care) (Type: NO_INTERVENTION): Providers randomized to usual care will receive no intervention.
- Open Encounter + Pre-commitment (Type: EXPERIMENTAL): There will be an enhanced EHR alert, known as a Best Practice Advisory \[BPA\], which will appear on each provider's EHR screen. We will also test a two-staged pre-commitment BPA in which the providers are prompted to discuss risks of the high-risk medications and share a handout about risks with their patients.
- Open Encounter + Follow-up booster (Type: EXPERIMENTAL): There will be an enhanced EHR alert, known as a Best Practice Advisory \[BPA\], which will appear on each provider's EHR screen. We will add a boostering option in the enhanced BPA, which is a provider-directed option for a follow-up in-basket message sent 4 weeks after the BPA is triggered.

Based on this trial design, predict the completion outcome and termination type (if applicable).